Full Breakdown
FDA Panel Endorses Grail’s Galleri Test, Hong Kong Doctors Remain Cautious
By Drooid · · How we work
Regulatory Milestone for Multi-Cancer Blood Testing
A U.S. Food and Drug Administration (FDA) advisory panel recently voted to support Grail’s Galleri test, marking the first regulatory endorsement of a multi-cancer early detection (MCED) blood assay. The panel’s recommendation paves the way for the test to seek pre-market approval, a step that could accelerate the availability of blood-based screening for several cancers in asymptomatic individuals.
How the Galleri Test Operates
Galleri belongs to a new class of MCED tests that analyze circulating tumour DNA (ctDNA) and other abnormal molecules in a single blood draw. By detecting molecular signatures associated with a range of malignancies, the assay aims to identify cancers before symptoms appear, potentially expanding screening beyond organ-specific programs such as mammography or colonoscopy.
Cautious Reception in Hong Kong
Despite the FDA panel’s backing, medical professionals in Hong Kong are expressing reservations about immediate adoption. Local experts note that the clinical utility of MCED tests remains uncertain, citing limited evidence on how early detection translates into improved patient outcomes. Physicians also point to the need for clear guidelines on follow-up diagnostics and treatment pathways after a positive Galleri result. Consequently, hospitals and clinics in the region are proceeding cautiously, awaiting further data and regulatory guidance before integrating the test into routine practice.
Potential Impact and Next Steps
If pre-market approval is granted, Galleri could become the first widely available blood test capable of screening for multiple cancers simultaneously. Proponents argue that such a tool could complement existing screening programs and address cancers that lack effective early-detection methods. However, the cautious stance of Hong Kong clinicians underscores the broader challenge of translating regulatory endorsement into clinical adoption, especially in markets where evidence of real-world benefit is still being gathered.